- Continued International Expansion Drives Sustained Growth
- All Key [...] Read more »
في نتائجها عن الفترة المنتهية في 30 سبتمبر 2025 استثمار القابضة تسجل ارتفاعاً في الإيرادات بنسبة 66% إلى 4.9 مليار ريال قطري وصافي الأرباح بنسبة 99% إلى 703 مليون ريال قطري
استمرار التوسع الدولي كمحرك رئيسي [...] Read more »
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
- FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density [...] Read more »
Swvl Grows 12.4% Quarter on Quarter in IFRS Revenue, 47% Quarter on Quarter Growth in Revenue in Constant Currency, and Achieves $0.8 Million in Net Profit in Q1 2025
Revenue growth of 12.4%, and 47% in constant currency for Q1 2025 over Q1 2024
Achieved $0.8 million in Net Profit in Q1 2025
Dollar pegged revenue increased [...] Read more »
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for [...] Read more »
منصة BTCC تحقق نموًا ملحوظًا في الربع الأول من عام 2025: حجم تداول قياسي بلغ 815 مليار دولار، وحماية معززة للمستخدم، والمزيد من المبادرات التي تركز على المستخدم
فيلنيوس، ليتوانيا, April 28, 2025 (GLOBE NEWSWIRE) —
Read more »
BTCC Exchange Achieves Remarkable Growth in Q1 2025: Record Trading Volume of $815 Billion, Strengthened User Protection, and More User-Centric Initiatives
VILNIUS, Lithuania, April 25, 2025 (GLOBE NEWSWIRE) — Read more »
Unipart announces record performance for year ending 31 December 2024
Highlights
- Turnover increased to £1,081.1m, up 3.2% year–on–year
- Underlying PBIT grew 29.5% to £28.1m
- Balance sheet strengthened – net cash position at [...] Read more »
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business [...] Read more »
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today [...] Read more »